Abstract
Four patent applications from Oxagen, its first applications relating to chemical entities, claim either novel indolylacetic acids per se or the use of indolyl acetic acid derivatives as orphan receptor CRTH2 antagonists. Blockade of this receptor inhibits much of the pro-inflammatory effects of prostaglandin PGD2 and is expected to provide a new method of treating allergic rhinitis and asthma.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
